Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn’s Perianal FistulasMichael De Gregorio, Nik S. Ding, Alexander Thompson et al.|Clinical Gastroenterology and Hepatology|2021Cited by 36
Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyRobert Gilmore, Jakob Begun, Richard Fernandes et al.|Intestinal Research|2024Cited by 13
P1064 Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to TofacitinibRobert Gilmore, Jakob Begun, Richard Fernandes et al.|Journal of Crohn s and Colitis|2024Cited by 2
Su437 HIGHER ANTI-TUMOUR NECROSIS FACTOR-ALPHA DRUG LEVELS ARE ASSOCIATED WITH IMPROVED RADIOLOGICAL OUTCOMES IN PATIENTS WITH PERIANAL FISTULISING CROHN'S DISEASE: A MULTICENTRE CROSS-SECTIONAL RETROSPECTIVE STUDYMichael De Gregorio, Nik S. Ding, Tanya Lee et al.|Gastroenterology|2021Cited by 1
Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the <scp>AURORA</scp> Study, Including the <scp>ANZIBD</scp> ConsortiumYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|JGH Open|2025Cited by 1